Re:Search Institution Members

155 Results for Members


Africa Fighting Malaria (AFM) is a non-profit health advocacy group whose mission is to make malaria control...

LifeArc is a self-funded charitable organisation committed to improving human health. The organisation has...

The Biomedical Center (INBIOMED) at the Central University of Ecuador is a center of excellence for biomedical...

The Council on Health Research and Development (COHRED), is an international non-governmental organization...

International Vaccine Institute (IVI) is an international organization dedicated to discovering, developing...

Mahidol University is research-led institution committed to developing innovative solutions to many of today’s...

166 Results for Collaborations


An investigator at the University of Buea will share PCR products of two identified biomarker candidates to detect adult stage O. volvulus with a researcher at the University of British Columbia (UBC). The UBC researcher will express and share the recombinant antigens to test for the antibody response with the goal of developing a point-of-care, antibody-based diagnostic device with the novel ability to detect adult stage O. volvulus.

Takeda will provide CIDR investigators with selected anti-apoptotic Bcl-2 family inhibitors for anti-parasitic drug discovery including P.falciparum, P.vivax, C.parvum, T.cruzi, Toxoplasma, and Leishmania sps. The investigators will test inhibitors in in vitro cell culture assays specific to each organism to identify candidates for further drug development. The next phase of this proposal will be to evaluate hit compounds in animal models.

A Northeastern University researcher synthesized an inhibitor previously demonstrated by a McGill researcher to inhibit malaria parasites. The McGill researcher utilized the compound to repeat his in vivo screens.

A UBC researcher will utilize his phage-display technology to develop new antibodies against Chagas disease host biomarkers identified by a McGill University researcher. Once developed, the antibody will be incorporated into the development of a diagnostic.

An investigator at the University of Yaoundé I, Cameroon is working to identify hit inhibitors of critical parasitic metabolic pathways to develop high-need drugs against HAT, leishmaniasis, and malaria. To support these efforts, Johnson & Johnson R&D’s computer-aided design team conducted analysis to select the best compounds for this collaboration and will be sharing the selected compounds with the University of Yaoundé I investigator.

Johnson & Johnson R&D will provide IDRI researchers with its Jump-stARter library to screen against intracellular M. tuberculosis and Leishmania parasites. The researchers will use IDRI’s high-content imaging system to perform the screens.

170 Results for Assets


This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by deleting the gene encoding the alpha-crystallin heat shock protein ("acr gene"). This gene contributes to the virulence of the organism. Since this strain is isogenic with virulent M. tuberculosis but for this deletion, the full complement of antigens remains present and the organism is viable in vitro. The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.
Intellectual property related to novel triazine and purine compounds that are inhibitors of key cysteine proteases (cruzain and Rhodesian) of the parasites Trypanosoma brucei rhodesiensi and Trypanosoma cruzi, the causative agents of African sleeping sickness and Chagas disease, respectively. NIH internal reference number: E-267-2008/0 More information is available here: Parasitic protozoa are responsible for a wide variety of infections in both humans and animals. Trypanosomiasis poses health risks to millions of people across multiple countries in Africa and North and South America. Visitors to these regions, such as business travelers and tourists, are also at risk for contracting parasitic diseases. There are two types of African trypanosomiasis, also known as sleeping sickness. One type is caused by the parasite Trypanosoma brucei gambiense, and the other is caused by the parasite Trypanosoma brucei rhodesiensi. If left untreated, African sleeping sickness results in death. Chagas disease, caused by Trypanosoma cruzi T. cruzi , affects millions of people in Mexico and South and Central America. Untreated, Chagas disease causes decreased life expectancy and can also result in death. The subject invention covers novel triazine and purine compounds that are inhibitors of key proteases cruzain and Rhodesian of the parasites Trypanosoma brucei rhodesiensi and Trypanosoma cruzi, respectively.
A new platform based on live or chemically inactivated killed rabies virus RABV virions containing EBOV glycoprotein GP in their envelope. In preclinical trials, immunization with such recombinant RABV virions provided excellent protection in mice against lethal challenge with the mouse adapted EBOV and RABV. More specifically, the inventors have developed a trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. The efficiency of these vaccines against challenge with EBOV, MARV and RABV will be studied in multiple preclinical studies. Live attenuated vaccines are being developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines are being developed for use in humans.
Leishmania parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites. Sand fly saliva is known to enhance Leishmania infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of Leishmania major, Phlebotomus papatasi, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent Leshmaniasis. The inventors have shown that one of these salivary proteins was able to protect vaccinated mice challenged with parasites plus salivary gland homogenates (SGH). A DNA vaccine containing the cDNA for the same protein provided this same protection. Protection lasted at least 3 months after immunization. The vaccine produced both intense humoral and delayed-type hypersensitivity (DTH) reactions. B cell-deficient mice immunized with the plasmid vaccine successfully controlled Leishmania infection when injected with Leishmania plus SGH.
Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia Trachomatis. More information is available here: . Chlamydia trachomatis is the leading sexually transmitted infectious agent in the United States, causing about 10 million new cases per year. It is a major cause of involuntary infertility in women. This invention claims the DNA sequences, and their encoded amino acid sequences, of the four variable domains from the major outer membrane protein MOMP of Chlamydia trachomatis, from the serovars Ba, D, E, F, G, H, I, J, K and L3. Serovars D, E, F, G, H, I, J, and K are the most common serovars associated with Chlamydia trachomatis caused sexually transmitted diseases. The claimed variable domains of MOMP contain the major antigen targets of protective immunity including neutralizing antibodies capable of preventing chlamydial infection. Thus, these sequences are useful for the development of recombinant protein, peptide, and DNA based vaccines against C. trachomatis caused sexually transmitted diseases. The variable domains also represent the primary serotyping antigenic determinants of C. trachomatis organisms making these variable domain sequences potential useful targets for the development of DNA or antibody based diagnostic assays for C. trachomatis. The invention is described further in Ying et al., Infection and Immunity 57, 1040-1049, 1989. Zhang et al., J. Infect. Dis. 176, 1035 - 1040, 1997 describes DNA vaccines utilizing MOMP DNA.
This invention is a continuation of U.S. Patent Application 07/912,294, which described Pfs28 a 28 kd protein found in Plasmodium gallinaceum. The new application describes a unique 28 kd protein expressed on the surface of ookinetes of Plasmodium falciparum (Pfs28). This protein is useful as a malaria transmission blocking vaccine. This technology contains claims to: the Pfs28 protein; Pfs28's amino acid and nucleic acid sequences; pharmaceutical compositions containing the polypeptide and nucleic acid sequences; and methods of preventing transmission of malaria using these pharmaceutical compositions. {RefNo is 1184 }